17.80

3.65% -0.7018

Adma Biologics Inc (ADMA)

Overview News Price History Option Chain Financials Discussions Forecast

Adma Biologics Inc stock is traded at $17.80, with a volume of 686.25K. It is down -3.65% in the last 24 hours and up +10.85% over the past month. ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Previous Close:

$18.50

Open:

$18.52

24h Volume:

686.25K

Relative Volume:

0.30

Market Cap:

$4.21B

Revenue:

$382.81M

Net Income/Loss:

$68.13M

P/E Ratio:

63.56

EPS:

0.28

Net Cash Flow:

$78.82M

1W Performance:

+5.41%

1M Performance:

+10.85%

6M Performance:

-1.46%

1Y Performance:

+184.74%

1-Day Range:

$17.64

$18.62

1-Week Range:

$15.88

$18.62

52-Week Range:

$5.88

$23.64

Adma Biologics Inc Stock (ADMA) Company Profile

Name

Adma Biologics Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

(201) 478-5552

Address

C/O ADMA BIOLOGICS, INC., RAMSEY

Employee

624

Twitter

@AdmaBiologics

Next Earnings Date

2025-03-03

Latest SEC Filings

ADMA's Discussions on Twitter

Compare ADMA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADMA Adma Biologics Inc	17.79	4.21B	382.81M	68.13M	78.82M	0.28
VRTX Vertex Pharmaceuticals Inc	500.77	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	680.11	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	579.80	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.63	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	250.04	26.76B	3.32B	-860.46M	-1.04B	-8.32

Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-19-23	Resumed	Raymond James	Strong Buy
Oct-13-22	Initiated	Mizuho	Buy
Nov-11-21	Upgrade	Raymond James	Outperform → Strong Buy
Nov-09-21	Initiated	Cantor Fitzgerald	Overweight
Jun-04-19	Initiated	Jefferies	Buy
Apr-15-19	Reiterated	H.C. Wainwright	Buy
Feb-07-19	Resumed	H.C. Wainwright	Buy
Dec-11-17	Reiterated	Maxim Group	Buy
Nov-14-17	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-23-17	Upgrade	Maxim Group	Hold → Buy
Aug-01-16	Downgrade	Maxim Group	Buy → Hold
Jul-25-16	Reiterated	Maxim Group	Buy
May-13-15	Reiterated	Maxim Group	Buy
Dec-08-14	Initiated	Oppenheimer	Outperform
Dec-01-14	Reiterated	Maxim Group	Buy

View All

Adma Biologics Inc Stock (ADMA) Latest News

09:30 AM

Should You Invest in Adma Biologics (ADMA) Based on Bullish Wall Street Views? - Nasdaq

09:30 AM

Mar 12, 2025

Adma Biologics (ADMA) Recently Broke Out Above the 50-Day Moving Average - Yahoo Finance

Mar 12, 2025

Mar 11, 2025

What's Driving the Market Sentiment Around ADMA Biologics? - Benzinga

Mar 11, 2025

Mar 10, 2025

Commit To Buy ADMA Biologics At $10, Earn 14% Using Options - Nasdaq

Mar 10, 2025

Bank of New York Mellon Corp Has $26.09 Million Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World

Mar 10, 2025

Mutual of America Capital Management LLC Has $614,000 Stake in ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World

Mar 10, 2025

Mar 09, 2025

Adma Biologics' Retail Traders Eye Higher Open After Blowout Q4, Strong Full-Year Outlook - MSN

Mar 09, 2025

Lost Money on ADMA Biologics, Inc. (ADMA)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire

Mar 09, 2025

Mar 08, 2025

Lisanti Capital Growth LLC Sells 59,565 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat

Mar 08, 2025

Mar 06, 2025

Mizuho lifts ADMA Biologics price target to $32, maintains Outperform - Investing.com

Mar 06, 2025

Mar 05, 2025

How Much Upside is Left in Adma Biologics (ADMA)? Wall Street Analysts Think 52.85% - MSN

Mar 05, 2025

ADMA Biologics Stock Climbs Amid Strong Earnings - TipRanks

Mar 05, 2025

ADMA Biologics (NASDAQ:ADMA) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World

Mar 05, 2025

Buy Rating Affirmed for ADMA Biologics Amid Transition to New Auditor and Growth Prospects - TipRanks

Mar 05, 2025

Mar 04, 2025

ADMA Biologics Earnings Call Highlights Strong Growth - TipRanks

Mar 04, 2025

ADMA Biologics Inc earnings beat by $0.31, revenue topped estimates - Investing.com Australia

Mar 04, 2025

BREAKING: Block & Leviton Investigating ADMA Biologics, - GlobeNewswire

Mar 04, 2025

BREAKING: Block & Leviton Investigating ADMA Biologics, Inc. for Securities Fraud Violations Following Delayed - EIN News

Mar 04, 2025

ADMA Biologics slips as 10-K delay overshadows earnings beat - MSN

Mar 04, 2025

ADMA Biologics stock slips on 10-K delay (ADMA:NASDAQ) - Seeking Alpha

Mar 04, 2025

ADMA Biologics, Inc. (NASDAQ:ADMA) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 04, 2025

ADMA Biologics Reports Strong 2024 Financial Performance - MSN

Mar 04, 2025